Objective. The purpose of this phase II study was to evaluate on an intent-
to-treat basis the activity and toxicity of single-agent vinorelbine (VRL)
as second-line chemotherapy of patients with platinum-resistant ovarian can
cer. Platinum-resistant disease was defined as disease refractory to or rel
apsing within 12 months after finishing platinum-containing chemotherapy.
Methods. VRL (30 mg/m(2)) was administered intravenously as a bolus injecti
on days 1 and 8 every 21 days. Initially, four courses of VRL were given. P
atients with responding or stable disease received four more courses of VRL
to a maximum of eight courses.
Results. Twenty-eight of 33 eligible patients were considered evaluable for
response. The overall response rate was 21% (7/33) (95% CI: 7-35), Median
time to progression was 3.1 months and median survival was 10.1 months. Tox
icity was generally mild. Leukopenia was the dose-limiting toxicity. CALGB
grade III/IV infection was observed in 15/0% of patients. The most importan
t nonhematologic toxicities were nausea and constipation. Grade III/IV naus
ea was observed in 6/0% and grade III/IV constipation in 3/3% of patients,
Peripheral neurotoxicity was only a minor problem with no grade III/IV toxi
city. No patients stopped treatment because of toxicity and no toxic death
was reported.
Conclusion. VRL was generally well tolerated, but the activity in platinum-
resistant ovarian cancer was only modest, although fully comparable to othe
r second-line treatments. Further studies are required to define the role o
f VRL in combination chemotherapy for ovarian cancer. (C) 2001 Academic Pre
ss.